NEW YORK, February 13, 2026 — Leads & Copy —
Psyence Biomedical Ltd. (Nasdaq: PBM) has entered into a put option agreement with PsyLabs, a developer and manufacturer of pharmaceutical-grade psychedelic compounds. The agreement grants PsyLabs the right, but not the obligation, to require Psyence BioMed to make a further equity investment in PsyLabs through a share-for-share exchange at fair market value.
The Put Option Agreement is part of a broader strategic and commercial relationship between the parties, including licensing arrangements that allow Psyence BioMed to access PsyLabs’ manufacturing capabilities. The agreement allows Psyence BioMed to acquire a significant equity stake in PsyLabs as its development and commercialization strategy evolves, securing a reliable supply of pharmaceutical-grade psychedelics for future clinical and commercial programs.
PsyLabs is an advanced manufacturer of pharmaceutical-grade psychedelic compounds, with expertise in scalable, GMP-compliant production. The agreement reflects the strategic value delivered by PsyLabs in accelerating the development of an alternative investigational product approved by the Australian regulator for clinical trials, which significantly de-risked Psyence BioMed’s clinical development pathway and mitigated supply-chain, regulatory, and execution risks.
Structuring the arrangement through a put option enables Psyence BioMed to preserve near-term financial flexibility by securing strategic manufacturing access and long-term alignment without needing to deploy further significant capital upfront. This allows the Company to preserve cash for clinical and regulatory execution as the pathway to commercialization unfolds. Certain executives of Psyence BioMed provide consulting services to PsyLabs in exchange for consulting fees and collectively own less than 13% of the outstanding shares of PsyLabs.
A Special Committee of independent and disinterested directors reviewed and ratified the Put Option Agreement and the transactions. The committee considered the commercial rationale for the transaction and an independent third-party valuation of PsyLabs in reaching its determination.
PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds, including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.
PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution. It is expanding its product pipeline to include ibogaine and other next-generation psychedelics.
Psyence Biomedical Ltd. (Nasdaq: PBM) specializes in psychedelic-based therapeutics and is focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to address unmet mental health needs.
Learn more at www.psyencebiomed.com and on LinkedIn.
Source: Psyence Biomedical Ltd.
